Corrigendum to: Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor (Cardiovascular Research (2008) 78, 3, (572-580) DOI: 10.1093/cvr/cvn048);Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor

Cardiovascular Research

Volumn 78, Issue 3, 2008, Pages 572-580

  Lee, Jung Sun ^a   Song, Sun Hwa ^b   Kim, Jeong Min ^a   Shin, In Soon ^a   Kim, Koung Li ^a   Suh, Yeon Lim ^a   Kim, Hak Zoo ^c   Koh, Gou Young ^c   Byun, Jonghoe ^d   Jeon, Eun Seok ^a   Suh, Wonhee ^b   Kim, Duk Kyung ^a  

^a Samsung Medical Center   (South Korea)

^b CHA University   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^d Dankook University   (South Korea)

Author keywords

Angiopoietin 1; Endothelium; Hypertension; Nitric oxide; Rarefaction; Target organ damage

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; ANTIHYPERTENSIVE AGENT; CARTILAGE OLIGOMERIC MATRIX PROTEIN ANGIOPOIETIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CAPILLARY FLOW; CAPILLARY RAREFACTION; CARDIOVASCULAR GENE THERAPY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ELECTROPORATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE TRANSFER; HEART INJURY; HEART PROTECTION; HYPERTENSION; KIDNEY INJURY; MALE; MICROVASCULARIZATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; RAT; RENAL PROTECTION; REPORTER GENE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

EID: 44449158072     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn253     Document Type: Erratum

References (23)

1. Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther 2006; 111:81-98.
2. Redon J. Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression? Curr Opin Nephrol Hypertens 2005;14:448-452.
3. Grimm RH Jr, Flack JM, Byington R, Bond G, Brugger S. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). Drugs 1990;40(Suppl. 2):38-43.
4. Samuelsson OG, Wilhelmsen LW, Svardsudd KF, Pennert KM, Wedel H, Berglund GL. Mortality and morbidity in relation to systolic blood pressure in two populations with different management of hypertension: The Study of Men Born in 1913 and the Multifactorial Primary Prevention Trial. J Hypertens 1987;5:57-66.
5. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation 2001;104:735-740.
6. Rizzoni D, Rodella L, Porteri E, Rezzani R, Guel. D, Piccoli A et al. Time course of apoptosis in small resistance arteries of spontaneously hypertensive rats. J Hypertens 2000;18:885-891.
7. Gobe G, Browning J, Howard T, Hogg N, Winterford C, Cross R. Apoptosis occurs in endothelial cells during hypertension-induced microvascular rarefaction. J Struct Biol 1997;118:63-72.
8. Cho CH, Kammerer RA, Lee HJ, Steinmetz MO, Ryu YS, Lee SH et al. COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci USA 2004;101:5547-5552.
9. Cho CH, Kammerer RA, Lee HJ, Yasunaga K, Kim KT, Choi HH et al. Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. Proc Natl Acad Sci USA 2004;101:5553- 5558.
10. Kim W, Moon SO, Lee SY, Jang KY, Cho CH, Koh GY et al. COMP-angiopoietin-1 ameliorates renal .brosis in a unilateral ureteral obstruction model. J Am Soc Nephrol 2006;17:2474-2483.
11. Cho CH, Kim KE, Byun J, Jang HS, Kim DK, Baluk P et al. Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood .ow. Circ Res 2005;97:86-94.
12. Lee JS, Byun J, Kim JM, Kim CY, Kim BM, Chung JH et al. Cardiac expression pro.les of the naked DNA vectors encoding vascular endothelial growth factor and basic .broblast growth factor. Exp Mol Med 2005;37:447-456.
13. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997; 99:1873-1879.
14. Antonios TF, Rattray FM, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension. Heart 2003;89:175-178.
15. Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension 1999;34:655-658.
16. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-1369.
17. Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 2003;30:32-38.
18. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and angiogenesis. Curr Pharm Des 2003;9:1733-1744.
19. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005;26:33-65.
20. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol 2006;291:H985-H1002.
21. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004;7:193-201.
22. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic .broblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-2634.
23. Cho CH, Sung HK, Kim KT, Cheon HG, Oh GT, Hong HJ et al. COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood .ow in a diabetic mouse model. Proc Natl Acad Sci USA 2006;103:4946-4951.